Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

SML0289

Sigma-Aldrich

Bromfenac sodium

≥98% (HPLC)

Synonyme(s) :

2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C15H11BrNNaO3
Numéro CAS:
91714-93-1
Poids moléculaire :
356.15
Numéro MDL:
MFCD03701673
Code UNSPSC :
12352200
ID de substance PubChem :
329825297
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Couleur

faintly yellow to dark yellow

Solubilité

H2O: ≥5 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

[Na+].Nc1c(CC([O-])=O)cccc1C(=O)c2ccc(Br)cc2

InChI

1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1

Clé InChI

HZFGMQJYAFHESD-UHFFFAOYSA-M

Informations sur le gène

human ... PTGS1(5742) , PTGS2(5743)

Application

Bromfenac sodium has been used:
  • to study its ability to bind to melanin
  • in the synthesis of bromfenac indolinone standard
  • to analyze its permeability in porcine conjunctiva

Actions biochimiques/physiologiques

Bromfenac exhibits antipyretic and prostaglandin synthetase inhibiting properties. It has therapeutic properties against the reduction of ocular pain and inflammation in postoperative cataract patients. Bromfenac acts as an effective agent against allergic conjunctivitis. It has the potential to treat acute muscle pain, osteoarthritis, and rheumatoid arthritis.
Bromfenac is a nonsteroidal anti inflammatory drug (NSAID) that inhibits both COX1 and COX2. It is used as an opthalmic analgesic.

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301

Classification des risques

Acute Tox. 3 Oral

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

Dexaméthasone powder, BioReagent, suitable for cell culture, ≥97%

Sigma-Aldrich

D4902

Dexaméthasone

Ester Carreño et al.
Clinical ophthalmology (Auckland, N.Z.), 6, 637-644 (2012-05-10)
Ophthalmic bromfenac sodium sesquihydrate is a topically applied selective cyclooxygenase (COX)-2 inhibitor. It is similar to amfenac, except for a bromine atom at the C(4) of the benzoyl ring position, which markedly affects its in vitro and in vivo potency
Neal A Sher et al.
Journal of refractive surgery (Thorofare, N.J. : 1995), 25(2), 214-220 (2009-02-27)
To compare the efficacy of two topical nonsteroidal anti-inflammatory drugs with regards to the control of pain, burning, photophobia, foreign body sensation, and epithelial healing rates in patients who underwent photorefractive keratectomy (PRK). Two hundred twelve eyes were randomized to
Christina Flaxel et al.
Retina (Philadelphia, Pa.), 32(3), 417-423 (2011-08-25)
To evaluate whether bromfenac eyedrops and ranibizumab intravitreal injections would provide added efficacy over ranibizumab alone. This was a single-site, multiinvestigator, prospective, open-label, interventional, Phase II study of patients with new or recurrent exudative/neovascular age-related macular degeneration. Thirty eyes were
Frank A Bucci et al.
Advances in therapy, 28(12), 1089-1095 (2011-11-23)
We compared the prostaglandin E(2) (PGE(2)) inhibition of three topical nonsteroidal antiinflammatory drugs (NSAIDs): ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% at peak dosing levels in patients previously scheduled to undergo phacoemulsification. This was a single-center, double-masked observational study of
Keith A Warren et al.
Retina (Philadelphia, Pa.), 30(2), 260-266 (2010-02-23)
The purpose of this study was to evaluate the addition of topical nonsteroidal antiinflammatory drugs (NSAIDs) to intravitreal corticosteroid and antivascular endothelial growth factor injections for the treatment of chronic cystoid macular edema. Thirty-nine patients with chronic pseudophakic cystoid macular
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique